Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

PURPOSE: Mammalian target of rapamycin (mTOR) inhibitors mediate AKT activation through a type 1 insulin-like growth factor receptor (IGF-1R)-dependent mechanism. Combining the mTOR inhibitor temsirolimus with cixutumumab, a fully human IgG1 monoclonal antibody directed against IGF-1R, was expected...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Naing, Aung, Kurzrock, Razelle, Burger, Angelika, Gupta, Sachin, Lei, Xiudong, Busaidy, Naifa, Hong, David, Chen, Helen X., Doyle, Lawrence A., Heilbrun, Lance K., Rohren, Eric, Ng, Chaan, Chandhasin, Chandtip, LoRusso, Patricia
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3176947/
https://ncbi.nlm.nih.gov/pubmed/21750201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2979
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items